Medecine des Maladies Metaboliques最新文献

{"title":"Infirmiers en pratique avancée et diabète : leadership multidimensionnel au cœur des parcours de soins","authors":"Agnès Lohues ,&nbsp;Léa Ouammou","doi":"10.1016/j.mmm.2026.01.012","DOIUrl":"10.1016/j.mmm.2026.01.012","url":null,"abstract":"<div><div>L’IPA exerçant avec des patients vivant avec un diabète incarne un nouveau modèle de leadership infirmier, fondé sur une expertise clinique avancée, la coordination des soins et l’éducation thérapeutique. Ce rôle complémentaire du médecin constitue un levier majeur d’amélioration de la qualité et de la continuité des soins.</div></div><div><div>Advanced practice nurses (APNs) in diabetology embody a new model of nursing leadership grounded in advanced clinical expertise, care coordination, and therapeutic patient education. This complementary role to physicians represents a major lever for improving the quality, continuity, and effectiveness of diabetes care.</div></div>","PeriodicalId":35047,"journal":{"name":"Medecine des Maladies Metaboliques","volume":"20 2","pages":"Pages 142-146"},"PeriodicalIF":0.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147551166","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Place de l’infirmière en pratique avancée (IPA) dans les soins de transition pédiatrie/adulte en diabétologie","authors":"Christine Vitrand ,&nbsp;Karen Bertet","doi":"10.1016/j.mmm.2026.01.013","DOIUrl":"10.1016/j.mmm.2026.01.013","url":null,"abstract":"<div><div>L’incidence du diabète de type 1 est en constante augmentation, et l’âge au diagnostic diminue, ce qui entraîne des durées de suivi plus longues et un risque accru de développer des complications aiguës ou chroniques. La période de transition entre les soins pédiatriques et les soins aux adultes est une période charnière de la prise en soin du fait d’un risque de rupture dans le suivi, initiée par la fin du suivi pédiatrique et le manque de repères dans le monde des adultes. Il est fondamental d’accompagner ces jeunes à quitter progressivement l’enfance et la pédiatrie, pour intégrer de façon sécurisée les soins d’adulte en diabétologie. Un parcours de soins de transition pour faire lien entre ces deux systèmes apparaît alors comme une évidence, mais soulève des problématiques nouvelles en lien avec la spécificité du public concerné. Les IPA ont toute leur place dans ce contexte, du fait de leurs compétences élargies, amenées par leur formation universitaire de grade master 2, centrée sur la clinique mais aussi l’éducation thérapeutique (ETP), la coordination, la formation et l’analyse de pratiques, ainsi que la recherche paramédicale.</div></div><div><div>The incidence of type 1 diabetes is constantly increasing, and the age at diagnosis is decreasing, leading to longer follow-up periods and an increased risk of developing acute or chronic complications. The transition period between pediatric and adult care is a pivotal time in patient care due to the risk of a break in follow-up, initiated by the end of pediatric monitoring and the lack of reference points in the adult world. It is essential to assist these young people as they gradually leave childhood and pediatric care behind and safely transition into adult diabetes care. A transitional care pathway to bridge the two systems seems determining, but raises new issues related to the specific nature of the population concerned. APNs have a key role to play in this context, owing to their broad skills, acquired through their master's degree-education, which focuses on clinical practice but also includes therapeutic education, coordination, training and analysis of practices, and paramedical research.</div></div>","PeriodicalId":35047,"journal":{"name":"Medecine des Maladies Metaboliques","volume":"20 2","pages":"Pages 133-141"},"PeriodicalIF":0.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147551167","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Issue Contents","authors":"","doi":"10.1016/S1957-2557(26)00065-9","DOIUrl":"10.1016/S1957-2557(26)00065-9","url":null,"abstract":"","PeriodicalId":35047,"journal":{"name":"Medecine des Maladies Metaboliques","volume":"20 2","pages":"Page iii"},"PeriodicalIF":0.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147551297","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"La révolution silencieuse de la pratique avancée","authors":"Sandrine Lablanche","doi":"10.1016/j.mmm.2026.01.019","DOIUrl":"10.1016/j.mmm.2026.01.019","url":null,"abstract":"","PeriodicalId":35047,"journal":{"name":"Medecine des Maladies Metaboliques","volume":"20 2","pages":"Pages 102-103"},"PeriodicalIF":0.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147551296","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Les jus végétaux","authors":"Jean-Michel Lecerf","doi":"10.1016/j.mmm.2025.10.011","DOIUrl":"10.1016/j.mmm.2025.10.011","url":null,"abstract":"<div><div>Les jus végétaux sont des boissons obtenues essentiellement à partir de graines de céréales, de légumineuses ou d’oléagineux. Ils ne peuvent être dénommés lait, à part le lait de coco et le lait d’amandes. Leur composition est très différente de celle du lait avec, pour la plupart une très faible teneur en protéines (excepté le jus de soja), en calcium et en d’autres micronutriments. De ce fait elles ne peuvent pas remplacer le lait et n’ont pas les mêmes effets sur la santé. Chez le nourrisson, cette substitution est extrêmement dangereuse. Chez l’adulte, ce sont des boissons désaltérantes, qui peuvent avoir leur place dans la diversité des boissons hors de l’eau.</div></div><div><div>Plant-based beverages are mainly obtained from grains, legumes or oilseeds. They cannot be named milks in France except coco milk and almond milk. Their nutritional composition is quite different from that of the mammal milk, with a very low content in proteins (except the soy juice), in calcium and in other micronutrients. For this reason the plant-based drinks cannot replace the milk and its health effects. In infants, this replacement is quite dangerous. In adults, these are refreshing beverages besides the other non-aqua drinks.</div></div>","PeriodicalId":35047,"journal":{"name":"Medecine des Maladies Metaboliques","volume":"20 1","pages":"Pages 90-94"},"PeriodicalIF":0.0,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146049196","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Fallait-il vraiment sucrer la glycémie ?","authors":"Jean-Michel Lecerf","doi":"10.1016/j.mmm.2025.10.012","DOIUrl":"10.1016/j.mmm.2025.10.012","url":null,"abstract":"","PeriodicalId":35047,"journal":{"name":"Medecine des Maladies Metaboliques","volume":"20 1","pages":"Pages 3-4"},"PeriodicalIF":0.0,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146049193","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"La couverture vaccinale : un enjeu de santé publique pour la prévention des infections chez les personnes vivant avec un diabète","authors":"Bernard Bauduceau ,&nbsp;Ariane Sultan","doi":"10.1016/j.mmm.2025.12.008","DOIUrl":"10.1016/j.mmm.2025.12.008","url":null,"abstract":"<div><div>L’insuffisance de la couverture vaccinale en France est la conséquence de craintes infondées de la population mais également de freins de la part des soignants. Cette constatation est regrettable alors que les vaccins ont fait la preuve de leur efficacité et de leur innocuité notamment chez les personnes à risque. Un effort de tous doit être mené pour convaincre les sujets réticents afin de permettre une meilleure protection vis-à-vis des infections accessibles à la vaccination. L’implication des soignants est primordiale en ce domaine en favorisant la communication entre tous les acteurs et en parvenant à un meilleur taux de couverture vaccinale chez les professionnels de santé.</div></div><div><div>The insufficient vaccination coverage in France is the result of unfounded fears among the population but also of hesitations among healthcare workers. This observation is regrettable given that vaccines have proven their effectiveness and safety, particularly among those at risk. Everyone must make an effort to convince reluctant individuals to provide better protection against infections that are susceptible to vaccination. The involvement of healthcare workers is essential in this area by promoting communication between all stakeholders and achieving a better vaccination coverage rate among healthcare professionals.</div></div>","PeriodicalId":35047,"journal":{"name":"Medecine des Maladies Metaboliques","volume":"20 1","pages":"Pages 42-46"},"PeriodicalIF":0.0,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146049235","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Place des infections dans les complications du diabète","authors":"Bernard Bauduceau ,&nbsp;Florence Galtier","doi":"10.1016/j.mmm.2025.12.002","DOIUrl":"10.1016/j.mmm.2025.12.002","url":null,"abstract":"<div><div>En France, la pathologie infectieuse constitue la 3^e cause de mortalité pour l’ensemble de la population. Le diabète, les comorbidités et le vieillissement favorisent les infections. Certaines de ces affections sont accessibles à la vaccination qui a fait de grands progrès ces dernières années notamment depuis l’épidémie de COVID-19. Les vaccins permettent ainsi d’éviter la survenue de nombreuses affections et limitent leurs conséquences. Malgré les bénéfices bien établis de la vaccination, la couverture vaccinale reste insuffisante tout particulièrement chez les malades à risque comme les personnes vivant avec un diabète.</div></div><div><div>In France, infectious diseases are the third leading cause of death for the entire population. Diabetes, its comorbidities, and aging all contribute to the development of infections. Some of these conditions are accessible to vaccination, which has made significant progress in recent years, particularly since the COVID-19 epidemic. Vaccines thus help prevent the onset of many conditions and limit their consequences. Despite this evidence, vaccination coverage is insufficient, particularly among at-risk individuals such as those living with diabetes.</div></div>","PeriodicalId":35047,"journal":{"name":"Medecine des Maladies Metaboliques","volume":"20 1","pages":"Pages 8-11"},"PeriodicalIF":0.0,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146049198","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Le triomphe de l’auto-immunité sur « l’horror toxicus » d’Ehrlich. Une courte histoire de l’auto-immunité","authors":"Jean-Louis Schlienger","doi":"10.1016/j.mmm.2025.10.007","DOIUrl":"10.1016/j.mmm.2025.10.007","url":null,"abstract":"&lt;div&gt;&lt;div&gt;Le triomphe de l’auto-immunité sur l’&lt;em&gt;horror toxicus&lt;/em&gt; d’Ehrlich. Une courte histoire de l’auto-immunité. Considéré comme inconciliable avec la vie par Paul Ehrlich, l’un des pères de l’immunologie, qui avait érigé en dogme au début du XX&lt;sup&gt;e&lt;/sup&gt; siècle « l’horror toxicus » pour affirmer qu’aucun organisme vivant ne pouvait produire des anticorps contre ses propres composants, le concept d’auto-immunité a dû attendre les années 1950 pour s’imposer. Les travaux de Noël Rose qui a immunisé des lapins contre la thyroglobuline ont montré que les anticorps anti-thyroglobuline pouvaient être responsables de lésions de la thyroïde. Réalisés en 1953, ses travaux n’ont été publiés qu’en 1956 tant il paraissait difficile alors d’aller contre la doxa en apportant la preuve d’une auto-immunisation pathogène. Dès 1956, Deborah Doniach, à Londres, a transposé ce phénomène de l’animal à l’homme en démontrant que la thyroïdite de Hashimoto était la conséquence d’une destruction de la glande par des autoanticorps anti-thyroglobuline. Par la suite, elle décrivit d’autres maladies auto-immunes d’organe comme l’anémie pernicieuse (de Biermer) ou la cirrhose biliaire primitive. En 1974, son laboratoire accueillit un jeune chercheur italien, G.F. Bottazo, qui attribua aussitôt le diabète de type 1 à la présence d’anticorps anti-îlots dont il identifia plusieurs types. Depuis, l’auto-immunité, dont le support génétique a été progressivement décrypté, est devenu un mécanisme physiopathologique majeur à l’origine de nombreuses maladies d’organe ou systémiques dont le diagnostic repose sur le dosage d’auto anticorps spécifiques.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;div&gt;Considered irreconcilable with life by Paul Ehrlich, one of the fathers of immunology, who had erected “horror toxicus” as a dogma at the beginning of the twentieth century to assert that no living organism could produce antibodies against its own components, the concept of autoimmunity had to wait until the 1950s to impose itself. The work of Noël Rose, who immunized rabbits against thyroglobulin, showed that anti-thyroglobulin antibodies could be responsible for thyroid damage. Carried out in 1953, his work was not published until 1956 as it seemed difficult to go against the doxa by providing proof of pathogenic autoimmunization. As early as 1956, Deborah Doniach, in London, transposed this phenomenon from animals to humans by demonstrating that Hashimoto's thyroiditis was the consequence of a destruction of the gland by anti-thyroglobulin autoantibodies. Later she described other autoimmune organ diseases such as pernicious anemia (Biermer's) or primary biliary cirrhosis. In 1974, his laboratory welcomed a young Italian researcher, G.F. Bottazo, who immediately attributed type 1 diabetes to the presence of anti-islet antibodies, of which he identified several types. Since then, autoimmunity, whose genetic support has been gradually deciphered, has become a major pathophysiological mechanism at the origi","PeriodicalId":35047,"journal":{"name":"Medecine des Maladies Metaboliques","volume":"20 1","pages":"Pages 60-66"},"PeriodicalIF":0.0,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146049200","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Les infections respiratoires graves chez le patient vivant avec un diabète liées au pneumocoque, à la coqueluche et au Sars-CoV-2","authors":"Lyse Bordier ,&nbsp;Bernard Bauduceau","doi":"10.1016/j.mmm.2025.12.004","DOIUrl":"10.1016/j.mmm.2025.12.004","url":null,"abstract":"<div><div>Les personnes vivant avec un diabète présentent un risque accru de développer des infections, en particulier respiratoires qui occupent une place prépondérante. La gravité de ces infections tient à la fois aux complications infectieuses elles-mêmes et au risque de décompensation du diabète ainsi qu’à l’aggravation des comorbidités associées. Si l’âge avancé constitue un facteur de risque important, la vulnérabilité des patients atteints de diabète de type 1, souvent plus jeunes, ne doit pas être négligée. Dans ce contexte, l’augmentation de la prévalence des infections invasives à pneumocoque, le retour périodique d’épidémies de coqueluche, la résistance croissante des bactéries aux antibiotiques ainsi que les mutations régulières du virus SARS-CoV-2 font de ces pathologies un véritable enjeu de santé publique. La vaccination constitue une mesure de prévention efficace. Pourtant, les recommandations en la matière restent insuffisamment appliquées et la couverture vaccinale chez ces patients à risque demeure largement insuffisante.</div></div><div><div>Patients living with diabetes are at greater risk of developing infections, primarily respiratory infections. Their severity is due to complications from the infection itself, but also to the risk of diabetes decompensation and associated comorbidities. The advanced age of patients plays a major role, but the risk of infection in patients living with type 1 diabetes, who are often younger, should not be underestimated. The increasing prevalence of invasive pneumococcal infections, the regular resurgence of whooping cough epidemics, the resistance of these bacteria to antibiotics, and the regular mutations of the Sars-CoV-2 virus make these infections a public health concern. Preventing these infections is possible through vaccination, but recommendations are insufficiently followed, and vaccination coverage among these at-risk patients remains highly inadequate.</div></div>","PeriodicalId":35047,"journal":{"name":"Medecine des Maladies Metaboliques","volume":"20 1","pages":"Pages 17-23"},"PeriodicalIF":0.0,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146049241","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}